Anlon healthcare limited IPO Overview
Anlon healthcare limited IPO is a Mainboard public issue offered through a Book Building issue with a total issue size of ₹— crores. The IPO price band is set at ₹91 per share, and retail investors can apply with a minimum investment of ₹14,924 as per IPO guidelines.
The Anlon healthcare limited IPO opens on 26 Aug 2025 and closes on 29 Aug 2025. The IPO allotment is expected to be finalized on 1 Sept 2025, and the equity shares are proposed to be listed on BSE, NSE on 3 Sept 2025.
Investors can refer to the Anlon healthcare limited IPO RHP-DRHP for detailed information. The issue is managed by Interactive Financial Services Ltd. as the book running lead manager, while Kfin Technologies Limited is the registrar to the IPO. Before investing, market participants often review IPO details, valuation, PE ratio, financials, and risk factors.
About anlon healthcare limited
The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products).
The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP.
In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs.
The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals.
The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards.
The company's product portfolio consists of sixty-five (65) commercialised products and twenty-eight (28) products at pilot stage and forty-nine (49) products at laboratory testing stage/ laboratory scale stage.
Products:
Pharma Intermediates:Cyanoethylbe nzoic acid, Ketonitrile and Methyldeslor atadine, these serve as a key starting material or as an advance intermediate for manufacturing of APIs.
Active Pharmaceutical Ingredients: The company’s APIs are key components in pharmaceutical products, delivering therapeutic effects. They are used in formulations like tablets, capsules, ointments, syrups, and in nutraceuticals, personal care, and veterinary products.
Competitive Strengths:
Strong product portfolio and scalable business.
Strong Promoters and Experienced Management Team.
High entry and exit barriers due to long customer approval cycles and strict product standards.
In-house Testing, Quality Control and Quality Assurance for quality control.
Focus on Quality, Environment, Health and Safety.
Investment Objective
Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company
Funding the working capital requirements of the Company
General corporate purposes